Your browser does not support the NLM PubReader view.
Go to this page to see a list of supporting browsers.

References

1. 

Schmidt EB, Hedegaard BS, Retterstol K. Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges. Heart 2020;106:1940-6. https://doi.org/10.1136/heartjnl-2019-316276

2. 

Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205. Erratum in: Atherosclerosis 2020;292:160-2. Erratum in: Atherosclerosis 2020;294:80-2. https://doi.org/10.1016/j.atherosclerosis.2019.12.004

3. 

Lee CJ, Yoon M, Kang HJ, et al. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. Korean J Med 2022;97:339-52. https://doi.org/10.3904/kjm.2022.97.6.339

4. 

Gallo A, Giral P, Carrie A, et al. Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. J Clin Lipidol 2017;11:704-11.e2. https://doi.org/10.1016/j.jacl.2017.03.016

5. 

Johnson KW, Dudley JT, Bobe JR. A 72-year-old patient with longstanding, untreated familial hypercholesterolemia but no coronary artery calcification: a case report. Cureus 2018;10:e2452.

6. 

Kim H, Lee CJ, Kim SH, et al. Phenotypic and genetic analyses of Korean patients with familial hypercholesterolemia: results from the KFH registry 2020. J Atheroscler Thromb 2022;29:1176-87.

7. 

Duell PB, Gidding SS, Andersen RL, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. Atherosclerosis 2019;289:85-93. https://doi.org/10.1016/j.atherosclerosis.2019.08.007

8. 

Trinder M, Francis GA, Brunham LR. Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease. JAMA Cardiol 2020;5:390-9. Erratum in: JAMA Cardiol 2020;5:488.

9. 

Mszar R, Grandhi GR, Valero-Elizondo J, et al. Absence of coronary artery calcification in middle-aged familial hypercholesterolemia patients without atherosclerotic cardiovascular disease. JACC Cardiovasc Imaging 2020;13:1090-2. https://doi.org/10.1016/j.jcmg.2019.11.001

10. 

Nasir K. Message for 2018 cholesterol management guidelines update: time to accept the power of zero. J Am Coll Cardiol 2018;72:3243-5. https://doi.org/10.1016/j.jacc.2018.10.006

11. 

Miname MH, Bittencourt MS, Moraes SR, et al. Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy. JACC Cardiovasc Imaging 2019;12:1797-804. https://doi.org/10.1016/j.jcmg.2018.09.019

12. 

Garg PK, Jorgensen NW, McClelland RL, et al. Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA). J Cardiovasc Comput Tomogr 2018;12:493-9.

13. 

Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. https://doi.org/10.1016/S0140-6736(14)61399-4

14. 

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. https://doi.org/10.1056/NEJMoa1615664

15. 

O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 2022;146:1109-19. https://doi.org/10.1161/CIRCULATIONAHA.122.061620